Search hospitals > Nevada > Henderson
OptumCare Cancer Care at Seven Hills
Claim this profileHenderson, Nevada 89052
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
144 reported clinical trials
2 medical researchers
Summary
OptumCare Cancer Care at Seven Hills is a medical facility located in Henderson, Nevada. This center is recognized for care of Cancer, Breast Cancer, Tumors, Lung Cancer, Adenocarcinoma and other specialties. OptumCare Cancer Care at Seven Hills is involved with conducting 144 clinical trials across 294 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
Top PIs
John A. EllertonOptumCare Cancer Care at Fort Apache4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
135 reported clinical trials
214 drugs studied
Alan K. IkedaAlliance for Childhood Diseases/Cure 4 the Kids Foundation6 years of reported clinical research
Expert in Tumors
Expert in Leukemia
51 reported clinical trials
108 drugs studied
Clinical Trials running at OptumCare Cancer Care at Seven Hills
Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Prostate Cancer
Gastric Cancer
Renal Cell Carcinoma
Tumors
Support Program
for Breast Cancer
This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at OptumCare Cancer Care at Seven Hills?
OptumCare Cancer Care at Seven Hills is a medical facility located in Henderson, Nevada. This center is recognized for care of Cancer, Breast Cancer, Tumors, Lung Cancer, Adenocarcinoma and other specialties. OptumCare Cancer Care at Seven Hills is involved with conducting 144 clinical trials across 294 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.